US Stocks Snap 3-Day Slide as Moderna Jumps 177% on Phase 3 Cancer Vaccine Data
Updated
Updated · Yahoo Finance · Aug 19
US Stocks Snap 3-Day Slide as Moderna Jumps 177% on Phase 3 Cancer Vaccine Data
3 articles · Updated · Yahoo Finance · Aug 19
Summary
The Dow rose 0.22% to 53,463, the S&P 500 gained 0.21% to 7,708, and the Nasdaq added 0.16% to 26,331, ending a three-session losing streak.
Easing bond-market pressure helped steady equities, even as U.S. national debt topped $40 trillion and Fed minutes showed support for another rate hike if inflation stays firm.
Moderna surged 177% after reporting positive Phase 3 results for its personalized mRNA cancer vaccine with Merck's Keytruda in melanoma; Merck climbed 13%.
Elsewhere, Sandisk fell 9% in broader chip weakness, while Viking Holdings dropped 4% after warning low river levels in Europe could disrupt cruise operations.
Target also supported sentiment with Q2 sales up 5.3% and same-store sales up 3.8%, offering a bright spot for investors watching consumer demand and rates.